In conclusion, our findings show that isolated gallic acid and its commercial standard are active against both stem/progenitor and differentiated CML cells and synergize with BCR::ABL1 TKIs through the inhibition of mitochondrial respiration and oncogenic signaling pathways. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.